- Home
- KTF vs IMNM Comparison
KTF vs IMNM Comparison
Compare KTF & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTF
- IMNM
- Stock Information
- Founded
- KTF 1988
- IMNM 2006
- Country
- KTF United States
- IMNM United States
- Employees
- KTF N/A
- IMNM N/A
- Industry
- KTF Finance Companies
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- KTF Finance
- IMNM Health Care
- Exchange
- KTF Nasdaq
- IMNM Nasdaq
- Market Cap
- KTF 349.0M
- IMNM 748.3M
- IPO Year
- KTF N/A
- IMNM 2020
- Fundamental
- Price
- KTF $8.85
- IMNM $8.84
- Analyst Decision
- KTF
- IMNM Strong Buy
- Analyst Count
- KTF 0
- IMNM 5
- Target Price
- KTF N/A
- IMNM $26.40
- AVG Volume (30 Days)
- KTF 103.3K
- IMNM 1.0M
- Earning Date
- KTF 01-01-0001
- IMNM 08-11-2025
- Dividend Yield
- KTF 3.54%
- IMNM N/A
- EPS Growth
- KTF N/A
- IMNM N/A
- EPS
- KTF 0.39
- IMNM N/A
- Revenue
- KTF N/A
- IMNM $10,938,000.00
- Revenue This Year
- KTF N/A
- IMNM N/A
- Revenue Next Year
- KTF N/A
- IMNM $310.65
- P/E Ratio
- KTF $23.10
- IMNM N/A
- Revenue Growth
- KTF N/A
- IMNM N/A
- 52 Week Low
- KTF $7.40
- IMNM $5.15
- 52 Week High
- KTF $9.12
- IMNM $16.81
- Technical
- Relative Strength Index (RSI)
- KTF 48.39
- IMNM 50.27
- Support Level
- KTF $8.71
- IMNM $8.35
- Resistance Level
- KTF $8.93
- IMNM $9.34
- Average True Range (ATR)
- KTF 0.06
- IMNM 0.53
- MACD
- KTF 0.02
- IMNM -0.07
- Stochastic Oscillator
- KTF 63.64
- IMNM 33.97
About KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.